A Young Lady With Myopericarditis: An Unusual Presentation of COVID-19 Infection

Md Nazmul Hasan 1, Adrita Afzal 2, Chowdhury Adnan Sami 1, Fazle R. Chowdhury 1, Din-E-Mujahid M. Faruque 3

1. Internal Medicine, Bangabandhu Sheikh Mujib Medical University, Dhaka, BGD. 2. Cardiology/Interventional Cardiology, National Institute of Cardiovascular Diseases, Dhaka, BGD. 3. Cardiology, Bangabandhu Sheikh Mujib Medical University, Dhaka, BGD

Corresponding author: Chowdhury Adnan Sami, sami.adnan.doc@gmail.com

Abstract

Fever, sore throat, cough, and shortness of breath are the characteristic clinical manifestations of coronavirus disease 2019 (COVID-19). As the epidemic spreads, it is evident that the infection can affect not only the lungs but also other organs. By attaching to the angiotensin-converting enzyme-2 receptor (ACE-2), the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces lung injury. SARS-CoV-2 can also cause damage to the heart and blood vessels as these organs have abundant ACE-2 receptors. Here, we present a 28-year-old lady with shortness of breath, chest pain, low blood pressure, and a pulse rate that fluctuates widely. She had SARS-CoV-2-induced myopericarditis after further testing. Initially, we treated her with high-dose prednisolone and other supportive medications. Then, we also added colchicine and ibuprofen due to the initial poor response, and the result was satisfying after two weeks of treatment.

Introduction

Since its emergence in Wuhan, China, coronavirus disease 2019 (COVID-19) has infected more than 8.6 million people, with over 13.5 thousand deaths in Bangladesh [1]. The typical manifestations of COVID-19 are fever, fatigue, and pulmonary symptoms [2]. However, various cardiac involvements, including myocardial infarction, myopericarditis, and arrhythmias, have been reported in the medical literature [3]. Zeng et al. described the first case of fulminant myocarditis and myocardial damage [3-4]. Myopericarditis is a rare and devastating complication of COVID-19 that can be easily missed. We present this case to emphasize the importance of vigilance so that physicians do not overlook myopericarditis in a COVID-19 patient.

Case Presentation

A 28-year-old woman presented to the COVID-19 dedicated medical ward with six days of fever, runny nose, exertional shortness of breath, palpitations, chest pain, and extreme weakness. She had no known comorbidities. A reverse transcription-polymerase chain reaction (RT-PCR) for COVID-19 was positive. During admission, physical examination findings showed that her temperature was 100°F, her blood pressure was 90/60 mm Hg, her pulse rate ranged from 50 to 140 beats per minute, and her respiratory rate was 30 breaths per minute. Although, her oxygen saturation in room air was 95% and remained normal. The only significant finding of the systemic examination was mild bilateral basal crepitation.

Her biochemical tests revealed lymphopenia and a high C-reactive protein (CRP). Nevertheless, her other inflammatory indicators, such as serum ferritin, D-dimer, lactate dehydrogenase (LDH), serum troponin-I, and brain natriuretic factor (pro-BNP), were normal (Table 1). The chest X-ray and high-resolution computed tomography (HRCT) scans were normal (Figures 1a, 1b). The electrocardiogram (ECG) demonstrated sinus tachycardia and a regular rhythm (Figure 2a). The echocardiography revealed normal wall motion at rest, a left ventricular ejection fraction (LVEF) of 60%, and an average left ventricular global peak longitudinal strain of 19.5% (Figure 2b). As a result of the fluctuating heart rate, a 24-hour Holter monitoring was performed, which revealed a sinus rhythm with an average rate of 91 beats per minute; the maximum heart rate was 145 beats per minute, and the minimum heart rate was 51 beats per minute (Figure 3). The cardiac magnetic resonance imaging (CMRI) showed hyperintensity signal changes in pericardium and myocardium in T-2 weighted and short tau inversion recovery (STIR) images, increased brightness (LGE) in a sub-epi-myocardial layer in phase-sensitive inversion recovery (PSIR), SI ratio over skeletal muscle 2.0, and prolonged global T-1 mapping time of 1149 ms (cut-off 1120 ms) and prolonged global T (Figure 4a-4f).
### Tests

|                | Results (normal) |
|----------------|------------------|
| Hemoglobin     | 12.9 gm/dl       |
| White blood cell count | 5.83 X10^9/L    |
| Lymphocyte count (%) | 14%             |
| Neutrophil count (%) | 78%             |
| Platelet count  | 273 X10^9/L      |
| Creatinine     | 1.13 mg/dl       |
| Alanine aminotransferase (ALT) | 22 IU/L         |
| Prothrombin time | 14 seconds      |
| C-reactive protein (CRP) | 4.7 mg/dl (3 mg/dl) |
| Ferritin       | 18.6 ng/ml (10-291 ng/ml) |
| Lactate dehydrogenase (LDH) | 240 IU/L        |
| D-dimer        | 0.44 mcg/ml (<0.50 mcg/ml) |
| Troponin-I     | <0.01 ng/ml (0.017-0.056 ng/ml) |
| Creatinine kinase (CK-MB) | 24 IU/L (3-25 IU/L) |
| Pro-brain natriuretic factor (pro-BNP) | 35.5 pg/ml (up to 178 pg/ml) |

### FIGURE 1: X-ray (a) and high-resolution computed tomography (HRCT) scan of the chest (b)
FIGURE 2: ECG demonstrated sinus tachycardia (a), echocardiography revealed normal wall motion and left ventricular ejection fraction (LVEF) of 60% (b)
FIGURE 3: 24-hour Holter monitoring revealed a sinus rhythm with an average rate of 91 beats per minute; the maximum heart rate was 145 beats per minute.
FIGURE 4: Cardiac magnetic resonance imaging showed hyperintensity signal changes in pericardium and myocardium

Therefore, myopericarditis caused by COVID-19 was identified. She was treated with corticosteroids and beta-blockers and observed for one week with no discernible improvement. In addition to steroid treatment, she received ibuprofen 400 mg thrice daily and colchicine 0.6 mg twice daily for 14 days. She responded satisfactorily to treatment and was stable over the follow-up period.

Discussion

The clinical presentation of COVID-19 varies from mild illness to major system involvement with fatal outcomes. In addition to other system involvement, the SARS-CoV-2 infection has been linked to cardiovascular complications such as myocardial infarction, thromboembolic events, and myopericarditis [3]. Sala et al. reported the first case of biopsy proved myocarditis in a COVID-19 patient [5]. There are two possible mechanisms to cause myocardial damage. Firstly, the SARS-CoV-2 virus directly inoculates into the myocardium by binding to transmembrane serine receptor-2 (TMPRSS2) and causes inflammation. Secondly, T lymphocyte-mediated cellular immune response to SARS-CoV-2 viral infection causes inflammation by cell-mediated cytotoxicity [6].

Many studies have suggested that myocarditis can present without typical respiratory symptoms, as in our case [7]. The clinical features of myopericarditis may be similar in COVID-19 as in other patients. In a review, Kariyanna et al. described dyspnea as the predominant clinical feature, followed by coughing, fever, and chest pain as the presenting symptoms in COVID-19-associated myopericarditis [8]. Another study found that 64% of patients with myocarditis in COVID-19 had presented with shock [9]. Our patient presented with fever, chest pain, shortness of breath, low blood pressure, and fluctuating heart rate, which is consistent with the literature.

For the diagnosis of myopericarditis in COVID-19, other possibilities need to be ruled out by history and investigations. The temporal relation between the symptoms and RT-PCR positivity proved this case. The coronary angiogram may be required in some cases to exclude other causes. An endo-myocardial biopsy is the gold standard for isolating viral particles from the myocardium [10-11]. The studies related to COVID-19 myopericarditis showed variable electrocardiographic (ECG) findings, a rise of troponin-I in about 91% of patients, and the LVEF was reduced in 60% of the patients [9]. Kariyanna et al. reported that pro-BNP was elevated in all analyzed studies [8]. In this case, we found normal troponin-I, pro-BNP, and ECG revealed sinus tachycardia and LVEF was normal in echocardiogram without wall motion abnormalities. Ultimately, CMRI confirmed the diagnosis of myopericarditis. Unfortunately, we could not do an endomyocardial biopsy due to the test’s unavailability, which is probably a limitation.

The treatment of viral myocarditis is supportive. Some authors advised using a high dose of steroids and immunoglobulin intravenously (IVIG) in COVID-19-associated myocarditis [12]. However, antiviral medication has an unproven role in treating myocarditis [13]. Individual cases were managed with colchicine 500 µgm twice daily and ibuprofen 400 mg thrice daily with prednisolone 30 mg daily with good results [14].
We also treated her with colchicine 600 µgm twice daily, ibuprofen 400 mg thrice daily, and steroid. She had significant improvement in her symptoms after two weeks of the treatment.

**Conclusions**

The outcome of myopericarditis in COVID-19 patients may be fatal and can cause rapid deterioration of the clinical condition. In our case, early identification, prompt treatment, and careful patient monitoring led to a satisfying outcome for the patient. So, the physician must be stringent about identifying the cases of myopericarditis as early as possible to salvage the life of the patients.

**Additional Information**

**Disclosures**

**Human subjects:** Consent was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

1. World Health Organization Coronavirus Disease 2019 (COVID-19) Dashboard: Bangladesh Situation. (2021). Accessed: June 15, 2021: https://covid19.who.int/region/searo/country/bd.
2. Asif T, Ali Z: Transient ST segment elevation in two patients with COVID-19 and a normal transthoracic echocardiogram. Eur J Case Rep Intern Med. 2020, 7:001672. 10.12890/2020_001672
3. Zeng BH, Liu YX, Yuan J, et al.: First case of COVID-19 complicated with fulminant myocarditis: a case report and insights. Infection. 2020, 48:773-7. 10.1007/s15010-020-01424-5
4. Pirzada A, Mokhtar AT, Moeller AD: COVID-19 and myocarditis: what do we know so far? J CJC Open. 2020, 2:278-85. 10.1016/j.jcjo.2020.05.005
5. Sala S, Peretto G, Gramegna M, et al.: Acute myocarditis presenting as a reverse Takao-Tuho syndrome in a patient with SARS-CoV-2 respiratory infection. Eur Heart J. 2020, 41:1861-2. 10.1093/eurheartj/ehaa286
6. Abdelnabi M, Eshak N, Saleh Y, Almaghraby A: Coronavirus disease 2019 myocarditis: insights into pathophysiology and management. Eur Cardiol. 2020, 15:e51. 10.15420/ecr.2020.16
7. Edwards S, Small JD, Geratz JD, Alexander LK, Baric RS: An experimental model for myocarditis and congestive heart failure after rabbit coronavirus infection. J Infect Dis. 1992, 165:134-40. 10.1093/infectdis/165.1.134
8. Kariyanna PT, Sutarjono B, Grewal E, et al.: A systematic review of COVID-19 and myocarditis. Am J Med Case Rep. 2020, 8:299-305. 10.12691/ajmcr-8-9-11
9. Sawalha K, Abozenah M, Kadado AJ, et al.: Systematic review of COVID-19 related myocarditis: insights on management and outcome. Cardiovasc Revasc Med. 2021, 23:107-15. 10.1016/j.carrev.2020.08.028
10. Yan L, Mir M, Sanchez P, Beg M, Peters J, Enriquez O, Gilbert A: COVID-19 in a Hispanic woman. Arch Pathol Lab Med. 2020, 144:1041-7. 10.5858/arpa.2020-0217-SA
11. Shiripanthong B, Nazarian S, Muser D, et al.: Recognizing COVID-19–related myocarditis: the possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm. 2020, 17:1463-71. 10.1016/j.hrthm.2020.05.001
12. Shi S, Qin M, Shen B, et al.: Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020, 5:802-10. 10.1001/jamacardio.2020.0950
13. Mele D, Flamigni F, Rapecci G, Ferrari R: Myocarditis in COVID-19 patients: current problems. Intern Emerg Med. 2021, 16:1123-9. 10.1007/s11739-021-02635-w
14. Shabbir A, Cunm CF, Elkington A, Tilling L, Stirrup I, Chan A, Boll S: Myopericarditis and myositis in a patient with COVID-19: a case report. Eur Heart J Case Rep. 2020, 4:1-6. 10.1093/ehjcry/tau270